Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about SMA: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
Knowledge base pages for this entity
| Target | Relation | Type | Str |
|---|---|---|---|
| No outgoing edges | |||
Hypotheses where this entity is a therapeutic target
Scientific analyses that reference this entity
neurodegeneration | 2026-04-16 | 1 hypotheses Top: 0.865
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| GWAS of plasma NfL in East Asian cohort | exploratory | Alzheimer's disease | 0.950 | 0.00 | human patients - East Asian co | proposed | N/A |
| GWAS of plasma pTau217 in East Asian cohort | exploratory | Alzheimer's disease | 0.950 | 0.00 | human patients - East Asian co | proposed | N/A |
| Dairy intake and dementia risk in Malmö Diet and Cancer cohort | clinical | Alzheimer's disease | 0.950 | 0.00 | Swedish community-based adults | proposed | N/A |
| GWAS of plasma pTau181 in East Asian cohort | exploratory | Alzheimer's disease | 0.950 | 0.00 | human patients - East Asian co | proposed | N/A |
| GWAS of plasma GFAP in East Asian cohort | exploratory | Alzheimer's disease | 0.950 | 0.00 | human patients - East Asian co | proposed | N/A |
| KEEPS Continuation: Long-term effects of menopausal hormone therapy on | clinical | Alzheimer's disease | 0.950 | 0.00 | recently menopausal women with | proposed | N/A |
| GWAS of composite biomarker score | exploratory | Alzheimer's disease | 0.900 | 0.00 | human patients - East Asian co | proposed | N/A |
| RBG treatment in ApoE-/- atherosclerosis mouse model | validation | atherosclerosis | 0.900 | 0.00 | ApoE-/- mice | proposed | N/A |
| APOE4 association with TDP-43 pathology in AD | exploratory | Alzheimer's disease | 0.750 | 0.00 | human patients | proposed | N/A |
| s:** - Biochemical binding assays measuring PROTAC selectivity for APO | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $100,000 |
| Alpha-Synuclein SAA Kinetics Study — Biological Staging Backbone for P | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Computational Modeling of Alpha-Synuclein Propagation in PD | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $2,280,000 |
| Alpha-Synuclein Seed Amplification Assay Validation | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $7,500,000 |
| Antiviral Therapy Trial for Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Combination Therapy Sequencing in Parkinson's Disease | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $2,280,000 |
| Genetic Risk Modifiers in DLB Phenotype | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $7,500,000 |
| DLB Treatment Response Biomarkers — Predicting Cholinesterase Inhibito | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Mechanism: Selective Vulnerability of Dopaminergic Neurons in Parkinso | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $3,000,000 |
| Selective Vulnerability of Dopaminergic Neurons — Mechanism and Protec | validation | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $160,000 |
| Endocannabinoid System Dysfunction Validation in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of [PMID:30335591] | Rusmini P, Cortese K, Crippa V, Cristofa | Autophagy | 2019 | 2 |
| Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegenerat [PMID:37995685] | Litvinchuk A, Suh JH, Guo JL, Lin K, Dav | Neuron | 2024 | 1 |
| The cell biology of APOE in the brain. [PMID:37805344] | Windham IA, Cohen S | Trends Cell Biol | 2024 | 1 |
| The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegene [PMID:37957317] | Maxine R Nelson, Peng Liu, Ayushi Agrawa | Nature neuroscience | 2023 | 1 |
| Atremorine in Parkinson's disease: From dopaminergic neuroprotection to pharmaco [PMID:34106485] | Cacabelos R, Carrera I, Martínez O, Alej | Med Res Rev | 2021 | 1 |
| APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therape [PMID:33340485] | Serrano-Pozo A, Das S, Hyman BT | Lancet Neurol | 2021 | 1 |
| Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. [PMID:31564456] | Long JM, Holtzman DM | Cell | 2019 | 1 |
| Age-dependent nigral dopaminergic neurodegeneration and α-synuclein accumulation [PMID:31120439] | Luo Z, Ahlers-Dannen KE, Spicer MM, Yang | JCI Insight | 2019 | 1 |
| Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. [PMID:31367008] | Yamazaki Y, Zhao N, Caulfield TR, Liu CC | Nat Rev Neurol | 2019 | 1 |
| Targeting alpha synuclein and amyloid beta by a multifunctional, brain-penetrant [PMID:31873106] | Yedlapudi D, Xu L, Luo D, Marsh GB, Todi | Sci Rep | 2019 | 1 |
| A systematic review and integrative approach to decode the common molecular link [PMID:28927418] | Guin D, Mishra MK, Talwar P, Rawat C, Ku | BMC Med Genomics | 2017 | 1 |
| Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associate [PMID:41905188] | Cetindag AC, Schipke CG, Esselmann H, Kr | The journal of prevention of A | 2026 | 0 |
| The role of genetic factors in the occurrence of levodopa-induced motor complica [PMID:40632937] | ["Radojevi\u0107 B", "Milovanovi\u0107 A | Neurological research | 2026 | 0 |
| ASS1 Promotes Atherosclerotic Inflammation Through the NLRP3/IL-33/ST2 Axis in O [PMID:41914296] | Wu S, Han F, Qiao Z, Yuan S, Bian X, Zha | Frontiers in bioscience (Landm | 2026 | 0 |
| Perioperative polygenic and APOE-based genetic risk assessment for neurocognitiv [PMID:40562635] | Thedim M, Hu J, Maher M, Wiener-Kronish | Br J Anaesth | 2026 | 0 |
| Increased genetic protection against Alzheimer's disease in centenarians. [PMID:40615639] | Bae H, Song Z, Ali A, Sasaki T, Tesi N e | Geroscience | 2026 | 0 |
| Integrative machine learning approach to risk prediction for dementia and Alzhei [PMID:40864401] | Stern A, Linial M | Geroscience | 2026 | 0 |
| Restoration of p53 mRNA combined with BRD4 silencing by brain targeted nanocapsu [PMID:41101204] | Sang Y, Cao Y, Li S, Quan Y, Wang S et a | Biomaterials | 2026 | 0 |
| Targeting KAT8 alleviates vascular senescence by modulating the INHBA/TGF-β path [PMID:41445196] | Lin Z, Xiong J, Zhang F, Zhang H, Zhu M | Mol Ther | 2026 | 0 |
| Menopause, cognition, and Alzheimer's disease risk. [PMID:41531227] | Samudra N, Vemuri M, Weitlauf J | Curr Opin Obstet Gynecol | 2026 | 0 |
Multi-agent debates referencing this entity
closed · Rounds: 4 · Score: 0.70 · 2026-04-21
closed · Rounds: 4 · Score: 0.70 · 2026-04-16
Hypotheses and analyses mentioning SMA in their description or question text
Score: 0.705 · unknown disease · 2026-04-26
Claudin-5 is the most abundant tight junction protein in brain endothelial cells and is specifically degraded during ear
Score: 0.685 · unknown disease · 2026-04-26
Plasma fibrinogen leaks across the compromised BBB and undergoes coagulation cascade activation and cross-linking by fac
Score: 0.681 · neurodegeneration · 2026-04-04
## Mechanistic Overview Temporal CAG Repeat Stabilization via CRISPR-Mediated DNA Mismatch Repair Modulation starts from
Score: 0.640 · neurodegeneration · 2026-04-21
**Molecular Mechanism and Rationale** The therapeutic strategy centers on modulating liquid-liquid phase separation (LL
Score: 0.610 · neuroscience · 2026-04-22
## Mechanistic Overview Blocking Tau Packaging into Small Extracellular Vesicles via ESCRT-III Pathway starts from the c
Score: 0.600 · unknown disease · 2026-04-26
A LASSO-optimized composite score integrating plasma GFAP, S100B, NFL, soluble PDGFR-β, and claudin-5 fragments to achie
Score: 0.580 · neurodegeneration · 2026-04-22
## Mechanistic Overview APOE4 Structural Correction by Small Molecule Correctors starts from the claim that modulating A
Score: 0.580 · neuroscience · 2026-04-22
## Mechanistic Overview Structure-interacting small molecules that stabilize the APOE4 molten globule domain (Domain III
Score: 0.560 · neurodegeneration · 2026-04-14
## Mechanistic Overview Complement C1q Suppression as Mechanism Linking Exercise Plasma to PV Interneuron Protection sta
Score: 0.550 · neurodegeneration · 2026-04-26
ALS-linked FUS mutations (P525L, R521C) impair nuclear import via karyopherin-β2 (Transportin-1), causing cytoplasmic ac
Score: 0.485 · unknown disease · 2026-04-26
Neurofilament light chain (NfL) is released from damaged neurofilaments into the extracellular space, flowing into CSF a
Score: 0.427 · biomarkers · 2026-04-26
Site-specific glycosylation patterns on circulating TREM2 ectodomain fragments reflect the metabolic state and activatio
Score: 0.405 · unknown disease · 2026-04-26
At doses of 25-50 mg, trazodone's metabolite mCPP exhibits partial agonist activity at melatonin MT1 receptors, phase-ad
Score: 0.400 · neurodegeneration · 2026-04-22
## Mechanistic Overview Small-Molecule Modulation of G3BP1 Condensate Dynamics via PRMT1 Methylation as a Therapeutic St
Score: 0.389 · biomarkers · 2026-04-26
This hypothesis proposes that plasma-derived exosomes carrying YKL-40, sTREM2, and neurogranin provide a superior biomar